American Journal of Microbiological Research
ISSN (Print): 2328-4129 ISSN (Online): 2328-4137 Website: http://www.sciepub.com/journal/ajmr Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
American Journal of Microbiological Research. 2016, 4(2), 64-67
DOI: 10.12691/ajmr-4-2-4
Open AccessArticle

Post Vaccination Evaluation of Anti-HBsAg Antibody Titers among Haemodialysis Patients

Raj kumar HRV1, Ramahrishna Devaki1 and Venkataramana Kandi2,

1Department of Microbiology, Kamineni Academy of Medical Sciences & Research Centre, L.B.Nagar, Hyderabad, Telangana, India

2Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, Telangana, India

Pub. Date: May 03, 2016

Cite this paper:
Raj kumar HRV, Ramahrishna Devaki and Venkataramana Kandi. Post Vaccination Evaluation of Anti-HBsAg Antibody Titers among Haemodialysis Patients. American Journal of Microbiological Research. 2016; 4(2):64-67. doi: 10.12691/ajmr-4-2-4

Abstract

Hepatitis B virus (HBV) is the second most common viral infection which poses threat of infection among health care workers and those individuals treated for various debilitated conditions in hospital settings. Patients undergoing haemodialysis are at a greater risk of acquiring HBV infection. Although HBV vaccination has been in use for almost three decades, it is not completely certain about its efficacy in long-term protection. Few studies in the past have emphasized the need for evaluation of anti-HBsAg antibody titers among high risk groups that include patients undergoing haemodialysis. Studies in the past have also noted that few vaccinated group do not respond to HBV vaccine and that few other group of vaccinated individuals develop inadequate antibody titers. The present study evaluated the antibody titers among haemodialysis patients and health care workers.

Keywords:
haemodialysis anti-HBsAg antibody titers Hepatitis B virus (HBV) infection non-responders

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  World Health Organization. Hepatitis B Fact sheet No 204. []. Available from: URL: http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed 7th March 2016.
 
[2]  Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2: 395-403.
 
[3]  K V Ramana etal, Seroprevalence of blood-borne viral infections in post HAART era at a tertiary care hospital in south India: A five year trend analysis (2008-2012) and a comprehensive review. British Journal of Medicine and Medical Research 2013; 3 ( 4) : 1929-1937.
 
[4]  Operational guidelines for hepatitis B vaccine introduction in the universal immunization programme (2011). http://www.searo.who.int/india/topics/routine_immunization/Operational_Guidelines_for_HepatitisB_ vaccine_introduction_in_UIP_2011.pdf?ua=1.
 
[5]  Zannolli R, Morgese G. Hepatitis B vaccine: current issues. Ann Pharmacother. 1997 Sep;31(9):1059-67.
 
[6]  Centers for Disease Control and Prevention (CDC). Updated CDC recommendations for the management of hepatitis B virus infected health-care providers and students. MMWR Recomm Rep 2012; 61: 1-12.
 
[7]  Centers for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). [Accessed 2011 Nov 25]. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6007a1.htm.
 
[8]  Chen DS. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J Hepatol 2009; 50: 805–816 poor response diabetes.
 
[9]  Goilav C, Piot P. Vaccination against hepatitis B in homosexual men. A review. Am J Med 1989; 87: 21S-25S immunocompromized only 45% develop protective ab titres.
 
[10]  Simmonds P, Midgley S. Recombination in the genesis and evolution of hepatitis B virus genotypes. J Virol 2005; 79: 15467-15476.
 
[11]  Hall AJ. Hepatitis B vaccination: protection for how long and against what? BMJ 1993; 307:276-7 protective antibody against infection and carriage.
 
[12]  Van Hattum J. Hepatitis B vaccine: simple and effective. Ned Tijdschr Tandheelkd. 1995 May;102(5):182-4.
 
[13]  Pokorska-Lis M, Marczyńska M. Are teenagers immunized in infancy still protected against hepatitis B?. Przegl Lek. 2010;67(1):13-7.
 
[14]  Schillie SF, Murphy TV. Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review. Vaccine. 2013 May 17;31(21):2506-16.
 
[15]  Said ZNA, Abdelwahab KS. Induced immunity against hepatitis B virus. World J Hepatol 2015; 7(12): 1660-1670.
 
[16]  West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine. 1996 14(11):1019-27.
 
[17]  Sjogren MH. Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination. Am J Med. 2005 Oct;118 Suppl 10A:34S-39S.
 
[18]  Walayat S, Ahmed Z, Martin D, Puli S, Cashman M, and Dhillon S. Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. World J Hepatol. 2015 Oct 28; 7(24): 2503-2509.
 
[19]  Godkin A, Davenport M, Hill AV. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology. 2005;41:1383-1390.
 
[20]  Egea E, Iglesias A, Salazar M, Morimoto C, Kruskall MS, Awdeh Z, Schlossman SF, Alper CA, Yunis EJ. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med. 1991;173:531-538.
 
[21]  Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet. 2000 Feb 12;355(9203):561-5.
 
[22]  Su T-H, Chen P-J. Emerging hepatitis B virus infection in vaccinated populations: a rising concern? Emerging Microbes & Infections. 2012;1(9):e27.
 
[23]  Jilg W, Schmidt M, Deinhardt F, Zachoval R. Hepatitis B vaccination: how long does protection last [letter]? Lancet 1984; 2:458.
 
[24]  Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366:1379–1384 more than 10 year protection.
 
[25]  Shaaban FA, Hassanin AI, Samy SM, Salama SI, Said ZN. Longterm immunity to hepatitis B among a sample of fully vaccinated children in Cairo, Egypt. East Mediterr Health J 2007; 13: 750-757 antibodies may decrease over time.
 
[26]  Abushady EA, Gameel MM, Klena JD, Ahmed SF, AbdelWahab KS, Fahmy SM. HBV vaccine efficacy and detection and genotyping of vaccineé asymptomatic breakthrough HBV infection in Egypt. World J Hepatol 2011; 3: 147-156 antibodies may decrease over time.
 
[27]  Ennis J, Stankus N. Acute hepatitis B infection in a long-term hemodialysis patient despite persistent natural immunity. Am J Kidney Dis. 2008 Nov;52(5):978-81.
 
[28]  Nahar K, Jahan M, Nessa A, Tabassum S. Antibody responses after hepatitis B vaccination among maintenance haemodialysis patients. Bangladesh Med Res Counc Bull. 2011 Dec;37(3):88-91.
 
[29]  Dong-II Shin, Kyu-Seon Song, Hee-Sung Park. Oral vaccination of mice with Tremella fuciformisyeast-like conidium cells expressing HBsAg. Biotechnol Lett 2015; 37: 539-544.